Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel mechanism of regulation of fibrosis in kidney tumor with tuberous sclerosis.

Molecular cancer - 25 May 2013

Liang Sitai, Cuevas Gabriela, Tizani Shaza, Salas Tiffanie, Liu Huijuan, Li Baojie, Habib Samy L

Abstract excerpt

BACKGROUND: Deficiency in tuberin results in activation the mTOR pathway and leads to accumulation of cell matrix proteins. The mechanisms by which tuberin regulates fibrosis in kidney angiomyolipomas (AMLs) of tuberous sclerosis patients are not fully known. METHOD: In the present study, we investigated the potential role of tuberin/mTOR pathway in the regulation of cell fibrosis in AML cells and kidney tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibrosis
Share to Intracellular Space
Share to Kidney Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis

Share to Tuberous Sclerosis Complex 2 Protein

Share to YY1 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 23705901
DOI: 10.1186/1476-4598-12-49
PMCID: PMC3681649

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel mechanism of regulation of fibrosis in kidney tumor with tuberous sclerosis.PMID 23705901Read ↗

Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.Semantic proximity Read ↗

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)Semantic proximity Read ↗

Mammalian Target of Rapamycin Signaling and Autophagy: Roles in Lymphangioleiomyomatosis TherapySemantic proximity Read ↗

Tuberous sclerosis complex exhibits a new renal cystogenic mechanismSemantic proximity Read ↗

Review: Mammalian Target of Rapamycin (mTOR) Pathway Is Critical in Developing Most Renal Cell Tumors.Semantic proximity Read ↗

Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.Semantic proximity Read ↗

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complexSemantic proximity Read ↗

TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis ComplexSemantic proximity Read ↗

Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.Semantic proximity Read ↗

Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.Semantic proximity Read ↗

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosisSemantic proximity Read ↗

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.